These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12838934)

  • 21. [Short and long-term therapeutic effects of rapamycin-eluting stent and paclitaxel-eluting stent in treatment of coronary disease with complicated lesions].
    Chen JL; Gao RL; Yang YJ; Qiao SB; Qin XW; Yao M; Liu HB; Xu B; Wu YJ; Yuan JQ; Chen J; Dai J; You SJ; Ma WH
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(31):2183-6. PubMed ID: 16321180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA perspective on clinical trial design for femoropopliteal stent correction of peripheral vascular insufficiency cardiovascular devices.
    Goode J; Sapirstein W; Zuckerman B
    Catheter Cardiovasc Interv; 2007 May; 69(6):920-1. PubMed ID: 17455345
    [No Abstract]   [Full Text] [Related]  

  • 23. [Is there an ideal stent for each type of coronary lesion?].
    Piscione F; Mazzarotto P; Capozzolo C; Galasso G; Spinazzola A; Sarno G; Guerrera L; Chiariello M
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 1):469-73. PubMed ID: 12497954
    [No Abstract]   [Full Text] [Related]  

  • 24. Failure to retrieve undeployed paclitaxel-eluting coronary stents.
    Roffi M; Luscher TF; Sutsch G; Maier W; Neuenschwanden C; Ramteke GB; Corti R; Eberli FR
    Am J Cardiol; 2006 Feb; 97(4):502-5. PubMed ID: 16461046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eosinophilic tissue response several weeks after sirolimus-eluting Cypher stent implantation within a bare metal stent in a coronary saphenous vein graft.
    Rittersma SZ; van der Wal AC; de Winter RJ
    Catheter Cardiovasc Interv; 2006 Jan; 67(1):38-40. PubMed ID: 16273582
    [No Abstract]   [Full Text] [Related]  

  • 26. Revascularization of the left anterior descending artery with drug-eluting stents: comparison with arterial off-pump surgery.
    Herz I; Mohr R; Moshkovitz Y; Ben-Gal Y; Adam SZ; Braunstein R; Uretzky G
    Heart Surg Forum; 2004; 7(5):E490-2. PubMed ID: 15799931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-eluting stents and the future of coronary artery bypass surgery: facts and fiction.
    Raja SG
    Ann Thorac Surg; 2006 Mar; 81(3):1162-71. PubMed ID: 16488758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents.
    Kereiakes DJ; Young JJ
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S48-58. PubMed ID: 15665798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents.
    Iijima R; Mehilli J; Schömig A; Kastrati A
    Minerva Cardioangiol; 2006 Oct; 54(5):539-55. PubMed ID: 17019392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cypher versus taxus: are there differences?
    Silber S
    J Interv Cardiol; 2005 Dec; 18(6):441-6. PubMed ID: 16336424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomedical Engineering Company announces its DISA S-Flex Coronary stent, Africa's first CE marked heart implant.
    Starke G
    Saudi Med J; 2000 Nov; 21(11):1090. PubMed ID: 11360078
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA and industry happenings.
    J Interv Cardiol; 2006 Apr; 19(2):211-3. PubMed ID: 16650252
    [No Abstract]   [Full Text] [Related]  

  • 33. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry.
    Zahn R; Hamm CW; Schneider S; Zeymer U; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Sabin G; Nienaber CA; Senges J;
    Am Heart J; 2006 Dec; 152(6):1146-52. PubMed ID: 17161068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA and industry happenings.
    J Interv Cardiol; 2007 Oct; 20(5):406-8. PubMed ID: 17880339
    [No Abstract]   [Full Text] [Related]  

  • 35. Food labeling: health claims; soluble fiber from certain foods and risk of coronary heart disease. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 May; 73(85):23947-53. PubMed ID: 18567170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Food labeling: health claims; soluble fiber from certain foods and risk of coronary heart disease. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(159):47828-9. PubMed ID: 18956498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis.
    Pinto Slottow TL; Waksman R
    Catheter Cardiovasc Interv; 2007 Jun; 69(7):1064-74. PubMed ID: 17525967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathology of drug-eluting stents: implications for coronary intervention.
    Finn AV; Nakazawa G; Virmani R
    Indian Heart J; 2007; 59(2 Suppl B):B41-9. PubMed ID: 19153436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA notifications. FDA tentatively approves 3-drug tablet in India.
    AIDS Alert; 2007 Apr; 22(4):43. PubMed ID: 17598192
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial.
    Pache J; Dibra A; Mehilli J; Dirschinger J; Schömig A; Kastrati A
    Eur Heart J; 2005 Jul; 26(13):1262-8. PubMed ID: 15737962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.